V5Z.F Sirnaomics Ltd.
- Market cap
- EUR 49.2M
- P/E
- -
- P/B
- 0.84x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is V5Z.F undervalued?
Graham numberThe Graham number of Sirnaomics Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sirnaomics Ltd. fundamental analysis
No fundamental analysis for Sirnaomics Ltd. yet.
Sirnaomics Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sirnaomics Ltd.
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs in the People's Republic of China. The company's therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates comprising STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; STP369 t…
Full company profileSirnaomics Ltd. financial statements
Sirnaomics Ltd. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 1.78M | 0.00 |
| Gross Profit | - | - | 0.00 | 1.20M | 0.00 |
| Operating Income | -56.8M | -91.2M | -77.2M | -35.9M | -14.9M |
| EBITDA | - | -92.6M | -77.8M | -43.6M | -12.0M |
| Net Income | -213M | -88.3M | -78.7M | -51.4M | -14.4M |
| EPS | -2.42 | -1.00 | -0.91 | -0.49 | -0.14 |
| Balance Sheet | |||||
| Total Assets | 241M | 164M | 75.8M | 28.3M | 20.6M |
| Total Liabilities | 30.4M | 52.4M | 51.3M | 44.3M | 45.1M |
| Shareholders' Equity | 212M | 122M | 40.2M | -1.68M | -9.91M |
| Cash & Short-term Investments | 212M | 105M | 23.9M | 11.8M | 13.5M |
| Cash Flow | |||||
| Operating Cash Flow | -57.0M | -88.7M | -70.3M | -19.7M | -9.20M |
| Capital Expenditure | 5.87M | 18.8M | 1.74M | 108K | 56.0K |
| Free Cash Flow | -62.8M | -108M | -72.0M | -19.8M | -9.25M |
| Ratios | |||||
| ROE | -100.7% | -72.4% | -195.8% | - | - |
| ROA | -88.5% | -53.9% | -103.8% | -181.4% | -69.9% |
| Net Profit Margin | - | - | - | -2,889.9% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sirnaomics Ltd. dividends
Sirnaomics Ltd. has not paid dividends in the last 5 fiscal years.
Who owns Sirnaomics Ltd.
- Insiders 26.81%
- Institutions 0.42%
- Public & others 72.77%
- Shares outstanding 111M
- Free float 86.1M
Sirnaomics Ltd. company profile
- Company name
- Sirnaomics Ltd.
- Ticker
- V5Z.F
- ISIN
- KYG2050P1028
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 37
- Fiscal year end
- December
- Address
- 20511 Seneca Meadows Parkway, Germantown, MD, United States, 20876
- Phone
- 301 740 1730
- Website
- sirnaomics.com
About Sirnaomics Ltd.
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs in the People's Republic of China. The company's therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates comprising STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; STP369 to treat head and neck cancer; and STP707 and STP355 to treat solid tumors. The company is also developing STP122G for the treatment of coagulation disorders; STP125G to treat hypertriglyceridemia; and STP144G, STP145G, and STP146G for the treatment of complement diseases. In addition, it is developing STP247G to treat complement diseases; STP152G to treat amyloidosis; STP705 for fat reduction; STP237G and STP251G for the treatment of hypertension in combination with familial hypertriglyceridemia; and STP136G to treat hypertension. The company was incorporated in 2007 and is headquartered in Germantown, Maryland.
Sirnaomics Ltd. management
5- Dr. Hung Fai Poon Ph.D.CEO & Executive Chairman · born 1979
- Dr. Yang Lu Ph.D.Honorary Scientific Scientific Officer · born 1956
- Mr. Jerry Tse M.Sc.Senior Vice President of Coporate Management
- Dr. Jake Tian Ph.D.Senior Vice President of R&D
- Mr. Yun Ting YuenCompany Secretary · born 1992